Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KT-333 |
Synonyms | |
Therapy Description |
KT-333 is a targeted protein degrader of Stat3, which decreases Stat3 downstream signaling and potentially induces tumor cell apoptosis and inhibits tumor growth (Blood (2021) 138 (Supplement 1): 1865). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KT-333 | KT333|KT 333 | STAT3 Inhibitor 26 | KT-333 is a targeted protein degrader of Stat3, which decreases Stat3 downstream signaling and potentially induces tumor cell apoptosis and inhibits tumor growth (Blood (2021) 138 (Supplement 1): 1865). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05225584 | Phase I | KT-333 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | Active, not recruiting | USA | 0 |